Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Metastases
Cutaneous or Subcutaneous Lymph Node
Liver Tumors

Interventions

DRUG: Talimogene Laherparepvec
DRUG: Pembrolizumab

Sponsor

Amgen

Collaborators

[object Object]